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The Human Epigenome Project aims to identify, catalogue, and interpret genome-wide DNA methylation phenomena.
Occurring naturally on cytosine bases at cytosine–guanine dinucleotides, DNA methylation is intimately involved in
diverse biological processes and the aetiology of many diseases. Differentially methylated cytosines give rise to
distinct profiles, thought to be specific for gene activity, tissue type, and disease state. The identification of such
methylation variable positions will significantly improve our understanding of genome biology and our ability to
diagnose disease. Here, we report the results of the pilot study for the Human Epigenome Project entailing the
methylation analysis of the human major histocompatibility complex. This study involved the development of an
integrated pipeline for high-throughput methylation analysis using bisulphite DNA sequencing, discovery of
methylation variable positions, epigenotyping by matrix-assisted laser desorption/ionisation mass spectrometry,
and development of an integrated public database available at http://www.epigenome.org. Our analysis of DNA
methylation levels within the major histocompatibility complex, including regulatory exonic and intronic regions
associated with 90 genes in multiple tissues and individuals, reveals a bimodal distribution of methylation profiles (i.e.,
the vast majority of the analysed regions were either hypo- or hypermethylated), tissue specificity, inter-individual
variation, and correlation with independent gene expression data.
Citation: Rakyan VK, Hildmann T, Novik KL, Lewin J, Tost J, et al. (2004) DNA methylation profiling of the human major histocompatibility complex: A pilot study for the
human epigenome project. PLoS Biol 2(12): e405.
Introduction
DNA methylation is indispensable for vertebrate genome
function. It is involved in diverse genomic processes such as
gene regulation, chromosomal stability, and parental im-
printing (Bird 2002), and interest in the function of DNA
methylation is further heightened by the various human
diseases associated with epigenetic dysfunction, a notable
example being cancer (Laird 2003). However, the DNA
methylation proﬁle of the human genome is still largely a
mystery.
The sequencing of the human genome (IHGSC 2001) and
creation of a whole-genome map of single nucleotide poly-
morphisms (SNPs) (Sachidanandam et al. 2001) laid the
foundation for the Human Epigenome Project (HEP). For
the HEP, we aim to analyse DNA methylation in the
regulatory regions of all known genes in most major cell
types and their diseased variants, along with producing high-
density snapshots of non-genic regions spread evenly across
the human genome. Although genome-wide DNA methyl-
ation analyses have been performed previously (Costello et al.
2000; Strichman-Almashanu et al. 2002), the HEP is the ﬁrst
systematic whole-genome study of DNA methylation at the
sequence level.
As a prelude to the HEP, here we report the results of the
HEP pilot study: DNA methylation proﬁling of the human
major histocompatibility complex (MHC). The MHC, located
on Chromosome 6 (6p21.3), is one of the most gene-dense
regions in the human genome, containing genes with a high
diversity of function, many of which are involved in the
innate and adaptive immune systems. We chose to analyse the
MHC for the pilot HEP study for three main reasons. (i) The
MHC is associated with more diseases than any other region
of the human genome, and therefore the generated data will
be of interest to researchers with diverse biomedical interests.
(ii) It is also the most polymorphic region in the genome, and
therefore the data will allow study of the potential effects of
the loss or gain of cytosine–guanine dinucleotide (CpG)
methylation sites (due to SNPs) on gene expression and
possibly other phenotypes. (iii) At the time when the HEP
pilot study was initiated in 1999 (Beck et al. 1999), the MHC
was one of the few regions within the human genome for
which ﬁnished sequence and annotation were readily
available (MHC Sequencing Consortium 1999).
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Open access, freely available online PLoS BIOLOGYUsing an integrated pipeline involving high-throughput
bisulphite DNA sequencing, we have determined the DNA
methylation levels within the vicinity of the promoter and
other relevant regions, such as CpG islands and ﬁrst exons
and introns of 90 genes within the 3.8-Mb MHC region in
multiple tissues and individuals. Our analysis reveals a
bimodal distribution of methylation levels, tissue speciﬁcity,
and inter-individual variation. We have also developed
matrix-assisted laser desorption/ionisation mass spectrometry
(MALDI-MS) assays for high-throughput epigenotyping of the
analysed regions. Finally, we have established a publicly
available database for the HEP data (http://www.epigenome.
org), which integrates, for the ﬁrst time, epigenetic informa-
tion with the existing genome annotation.
Results/Discussion
For the DNA methylation proﬁling of the human MHC, the
following regions of interest (ROIs) were chosen: (i) a potential
regulatory region for each gene and (ii) the most CpG-dense
region of each gene. It is well established that epigenetic
modiﬁcations at regulatory regions, in particular promoters,
correlate with the transcriptional state of the cognate gene
(reviewed in Bird 2002). Because the precise locations of
promoters within the human MHC were unknown at the time
this study was initiated, we surmised that analysing a region
from 2 kb upstream to 500 bp downstream of the annotated
start codon would, in many cases, include the promoter
region. Such regions were designated as ‘‘upstream’’ ROIs.
ROIs representing the most CpG-dense region within each
gene were deﬁned for the region from 500 bp downstream of
the annotated start codon to the end of the gene and did not
exceed a total length of 2.5 kb. These ROIs were named
‘‘intragenic’’. For longer genes, more than one intragenic ROI
was chosen. Within each ROI, we used the amplicon with the
highest CpG density that could be successfully ampliﬁed.
Other amplicons, if used, were chosen based on the ranking of
their CpG density. Wherever possible, CpG islands associated
with genes were included. (CpG islands have been deﬁned by
Bird [1986] as a contiguous window of DNA of at least 200 bp
in which the G þ C content is at least 50% and the ratio of
observed over expected CpG frequency is greater than 0.6. We
used a slightly stricter deﬁnition: regions of at least 400 bp in
which the G þ C content is at least 50% and the ratio of
observed over expected CpG frequency is greater than 0.6.) All
known repeat sequences were avoided during amplicon
design. Methylation was analysed in seven human tissues—
adipose, brain, breast, liver, lung, muscle, and prostate—with
multiple samples from different individuals for all tissues
(except adipose) (see Table S1).
Figure 1 shows the locations and the coverage provided by
the bisulphite PCR amplicons across the 3.8-Mb human MHC
in the context of annotated genes, CpG content, CpG islands,
and SNPs extracted from the SNP database (http://
www.ncbi.nlm.nih.gov/SNP). A total of 253 unique amplicons
were successfully analysed (Table 1). On average, the
amplicons were 438 bp in length (which is close to the
optimum amplicon length for the bisulphite PCR), were
relatively GC-rich (average G þ C . 50%), and had a high
density of CpGs (approximately 1 CpG/31 bp). Ninety genes
(i.e., more than 70% of all expressed genes within the MHC)
were represented by at least one amplicon. Of the analysed
CpG sites, 80% displayed methylation levels that varied (i.e.,
by more than 20%) either between individuals and/or tissues,
Table 1. Amplicon Statistics
Statistic Value
Amplicons analysed 253
Mean amplicon length (in basepairs, 6 sd) 438 6 65
Mean number of CpGs per amplicon (6 sd) 13 6 8
Mean G þ C percentage of amplicons (6 sd) 56 6 7
Mean ratio of observed CpG sites/expected CpG sites per amplicon (6 sd) 0.48 6 0.2
Measurements for which methylation data were obtained
a 134,065
Unique CpG sites analysed 3,273
Proportion of unique CpG sites with methylation differences . 50%
b 0.45
Proportion of unique CpG sites with methylation differences . 20%
c 0.81
Proportion of unique CpG sites with methylation differences . 20% between tissues
d 0.41
CpG sites that overlap with known SNPs 101
Expressed MHC genes represented by at least one amplicon 90
Upstream amplicons 72
Intragenic amplicons 181
Amplicons that fulfil CpG island definition 27
a Total number of CpG sites for which methylation levels were determined from forward and reverse sequencing.
b Proportion of unique CpG positions analysed that showed a difference of 50% or greater between the minimum and maximum methylation levels observed at that site
across all samples.
c Proportion of unique CpG positions analysed that showed a difference of 20% or greater between the minimum and maximum methylation levels observed at that site
across all samples.
d Proportion of unique CpG positions analysed that showed a difference of 20% or greater between the minimum and maximum average methylation levels observed at
that site across different tissue types. The mean methylation for a unique CpG in a tissue was calculated by averaging the measurements of the individual samples from that
tissue type.
DOI: 10.1371/journal.pbio.0020405.t001
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Human Epigenome ProjectFigure 1. Map of the Human MHC Showing Coverage and Locations of the Bisulphite PCR Amplicons for Which Methylation Data Have Been Generated
Tracks from top to bottom are as follows. (1) CpG content—the proportion of CpGs in 8-kb windows. The expected proportion of CpG
dinucletides is 0.04 based on the background base composition of Chromosome 6 (Mungall et al. 2003). (2) Random SNP density in 1,000-bp
PLoS Biology | www.plosbiology.org December 2004 | Volume 2 | Issue 12 | e405 2172
Human Epigenome Projectwindows. (3) Location of predicted CpG islands. (4) Bisulphite PCR amplicons. (5) Location of annotated gene structures. Right and left arrows
indicate gene structures on the sense and antisense strand, respectively. Ofﬁcial gene symbols are used where available.
DOI: 10.1371/journal.pbio.0020405.g001
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Human Epigenome Projectsuggesting that the potential information content of the
selected amplicons was relatively high.
Quantification of DNA Methylation by Direct Sequencing
of Bisulphite PCR Products
We analysed DNA methylation using bisulphite sequencing
(Olek et al. 1996). In the presence of sodium bisulphite,
unmethylated cytosines are converted to uracil, whereas
methylated cytosines are unreactive under the same con-
ditions. After bisulphite treatment the DNA is subjected to
PCR and sequencing. Methylated cytosines are detected as
cytosines in the sequencing reaction, whereas all unmethy-
lated cytosines appear as thymidines. Traditionally, bisulphite
PCR analysis involves sequencing multiple sub-clones of the
bisulphite PCR product. This approach is time-consuming,
and there have also been reports of bias (Grunau et al. 2001)
and hetero-duplex ampliﬁcation (Sandovici et al. 2003)
during sub-cloning of bisulphite PCR products. We se-
quenced the bisulphite PCR products directly with the same
primers used in the PCR and developed software, called
ESME (Lewin et al. 2004), to determine the DNA methylation
levels from the sequence trace ﬁles. Brieﬂy, ESME performs
quality control, normalises signals, corrects for incomplete
bisulphite conversion, and maps positions in the trace ﬁle to
CpGs in the reference sequence. The program calculates
methylation levels by comparing the C to T peaks at CpG
sites, with the ability to discriminate levels of methylation
that differ by as little as 20%. Methylation estimation by
ESME at any given CpG site is the average from all the copies
generated during PCR and is, therefore, compared to sub-
cloning, a more accurate representation of the methylation
level. Furthermore, we reanalysed the methylation levels of 77
amplicons by MALDI-MS, which allows for discrimination of
methylation levels that differ by as little as 5% (Tost et al.
2003). Figure 2 shows the comparison of the two methods,
demonstrating a concordance rate of 88% between ESME
and MALDI-MS.
The HEP Database
To make the data generated in this study a publicly
available resource, we have designed a Web-based, EN-
SEMBL-like genome browser (http://www.epigenome.org) that
allows easy access to the data from the pilot HEP study
(Figure 3A and 3B). Methylation levels calculated by ESME are
displayed in a colour-coded matrix. Rows represent the
averages of forward and reverse sequences for various tissues
while columns represent individual CpG sites. Each matrix
square therefore represents the average methylation level at a
given CpG site for a given tissue. Multiple data rows are
available for all tissues (except adipose). Clicking on a square
in the genome browser reveals the level of methylation
observed at that particular CpG site (the average of the
forward and reverse sequence) and information about the
tissue source. Additional annotation includes chromosome
coordinates, CpG islands, SNPs, ENSEMBL and high-quality,
manually curated Vertebrate Genome Annotation database
transcripts, the ROIs, and amplicon and primer sequences.
The browser provides a zoom function to view the genomic
sequence (Figure 3B), and a link to ENSEMBL facilitates
access to additional information and the ENSEMBL search
engines. The data from the full-scale HEP will be made
available via the same browser, providing a novel public
resource for the research community.
Methylation Profile Characteristics of the MHC
The methylation proﬁle of the human MHC region appears
to be strongly bimodal, with over 90% of the amplicons being
either relatively hypomethylated (i.e., median methylation of
amplicon 30% or less) or relatively hypermethylated (i.e.,
median methylation of amplicon 70% or greater) (Figures 3A
and 4). Re-analysis of a subset of the data by MALDI-MS
conﬁrmed the bimodality of the methylation proﬁle (Figure
4). Extensive bimodality of genomic methylation proﬁles has
been observed by several authors (reviewed in Bird 2002).
Furthermore, the experiments of Lorincz et al. (2002) suggest
that the extremes of methylation proﬁles may in fact be the
most stable states within the genome. Lorincz et al. showed
that a high density of methylation at a proviral construct is
stably propagated in vivo, whereas a low density of proviral
methylation is inherently unstable, with daughter cells
harbouring proviral cassettes that are demethylated or de
Figure 2. Comparison of Methylation
Measurements Obtained Using MALDI-MS
with Those from ESME Analysis of Directly
Sequenced Bisulphite PCR Products
(A) Comparison of methylation measure-
ments obtained by MALDI-MS (x-axis)
with ESME-processed data from se-
quencing (y-axis). Methylation rates at
CpGs from forward and reverse sequenc-
ing were binned into ten intervals from
zero to one using corresponding MAL-
DI-MS measurements at the same CpGs
and in the same tissue samples.
(B) Comparison of methylation measure-
ments obtained from ESME-processed
data (x-axis) with measurements from
MALDI-MS (y-axis). Methylation rates
from MALDI are binned as in (A), using
the corresponding methylation values
from sequencing. Red lines show the
means of the binned rates; bars show the
standard deviations. The overall correla-
tion of the data is 0.887. Data points that are not around a methylation rate of zero or one are covered by few measurements because of the
bimodal distribution of methylation measurements.
DOI: 10.1371/journal.pbio.0020405.g002
PLoS Biology | www.plosbiology.org December 2004 | Volume 2 | Issue 12 | e405 2174
Human Epigenome Projectnovo methylated. It must be noted that even though the
amplicons displayed hypo- or hypermethylated proﬁles, small
variations in the levels of methylation at individual CpG sites
within an amplicon were also frequently observed. Although
there may be technical reasons for this heterogeneity,
numerous studies (using a variety of techniques) have shown
that the methylation proﬁle of a given region in vivo is rarely
homogenous (Costello et al. 2000; Kondo et al. 2000; Grunau
et al. 2001; Cui et al. 2003). The functional outcome of these
small variations, particularly when they exist between tissues
or individuals, remains to be elucidated.
Comparison of the methylation values for upstream
amplicons (median methylation of 10%) versus intragenic
amplicons (median methylation of 86%) revealed that up-
stream amplicons were more likely to be hypomethylated (p ,
0.0001). Interestingly, within the upstream category we found
that CpG sites located within the 59 UTR were less likely to be
methylated (median methylation of 7%) than the CpG sites
located within 2 kb of the ﬁrst start codon but not within the
59 UTR (median methylation of 14%) (p , 0.0001). Within the
intragenic category, we found that CpG sites located within
introns (median methylation of 84%) were less likely to be
methylated than CpG sites located within exons (median
methylation of 89%) (p , 0.0001). Whether these signiﬁcant
but small differences reﬂect any bias for the presence of
regulatory elements close to the transcriptional start site or
within introns, or some other functional consequence, is
currently hard to assess.
Analysis of Heterogeneously Methylated Regions
Fourteen amplicons displayed signiﬁcant heterogeneous
methylation proﬁles (i.e., median methylation between 30%
and 70%) (see Figure 3A). These might represent differ-
entially methylated regions at which parental alleles display
reciprocal methylation proﬁles that are determined by the
parent-of-origin of the allele, or regions that were heteroge-
neously methylated on both alleles. Our sequencing method
could not discriminate between these two possibilities, and
none of these regions corresponded to known imprinted sites
within the human genome. We therefore sub-cloned the PCR
products and sequenced individual sub-clones of ten differ-
ent heterogeneously methylated amplicons and used poly-
morphisms to discriminate between the parental alleles. The
overall methylation proﬁles determined by sequencing
individual sub-clones were consistent with those obtained
by direct sequencing of the bisulphite PCR products. None of
Figure 3. The HEP Database
(A) We have created a Web-based,
ENSEMBL-like genome browser for dis-
playing HEP data that is publicly avail-
able at http://www.epigenome.org. The
methylation levels calculated by the
ESME software are displayed in the form
of a matrix. Each matrix contains the
data obtained from all the samples of
one amplicon. Each colour-coded square
(yellow represents 0% methylation, blue
represents 100% methylation, and green
represents intermediate levels) within
the matrix represents one CpG site.
Clicking on a square reveals the tissue
source of the sample and the level of
methylation observed at that particular
CpG site. Grey squares indicate CpG
sites for which methylation levels could
not be determined. Each row of squares
represents all the CpG sites for one
sample of a particular amplicon, and
the samples are grouped by tissue type.
The red bar indicates the genomic
region analysed. Also shown are chro-
mosome coordinates, CpG islands, SNPs,
and ENSEMBL and high-quality, man-
ually curated VEGA transcript informa-
tion. The HEP database links to the
Ensembl genome browser, providing
additional information about the region
of interest. The example shows ampli-
cons within the SynGAP 1 gene that
correspond to regions that were deter-
mined to be hypomethylated (second
amplicon from the left), hypermethy-
lated (ﬁrst and ﬁfth amplicons), and
heterogeneously methylated (fourth am-
plicon). Insufﬁcient data were obtained
for the third amplicon.
(B) By using the zoom function, the user
can view the complete DNA sequence for
the analysed amplicon.
DOI: 10.1371/journal.pbio.0020405.g003
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Human Epigenome Projectthe six amplicons for which polymorphisms were found
showed allele-speciﬁc methylation (data not shown). This is
consistent with the fact that so far there have been no reports
of imprinted regions within the human MHC. Since these
amplicons were heterogeneously methylated to a similar
extent in samples from various tissues and individuals, they
might represent regions where maintenance of a speciﬁc
epigenetic state is not essential. It is also possible that these
regions are located at the boundaries of hypermethylated
regions, and, consequently, the methylation levels are ‘‘trail-
ing off’’. However, both these possibilities contradict models
that suggest that the genome prefers to maintain methylation
proﬁles in bimodal states.
Interestingly, a few regions were heterogeneously methy-
lated in some tissues only, suggesting that the tissue sampled
was a mosaic of several sub-types among which the
methylation proﬁle at certain genes varied, or that the region
displays tissue-speciﬁc parental imprinting similar to the
insulin-like growth factor 2 (IGF2) gene, which is imprinted in all
tissues except brain (Pham et al. 1997).
Direct sequencing of the heterogeneously methylated
amplicons was unsuccessful in a small proportion of cases.
Possible reasons include incomplete bisulphite conversion
and genetic polymorphisms within the primer binding site.
We also noticed a mobility shift of the sequence in a few cases.
This occurs because a population of bisulphite PCR products
generated from a heterogeneously methylated region con-
tains a mixture of molecules, some with cytosines at certain
CpG sites (i.e., initially methylated) and others with thymi-
dines at those CpG sites (i.e., initially unmethylated). When
these PCR products are sequenced directly, the cumulative
effect of the molecular weight difference between cytosines
and thymidines is that some molecules migrate faster than
others during capillary electrophoresis. The sequence trace
therefore contains two traces that do not perfectly overlap,
resulting in erroneous estimation of methylation levels. Such
sequences were excluded from further analyses.
Analysis of CpG Islands
CpG islands are GC-rich regions that contain a high density
of CpGs and are positioned at the 59 ends of many human
genes (reviewed in Bird 2002). Although most CpG islands
remain hypomethylated throughout development in all
tissues (Antequera and Bird 1993), regardless of expression
state, a small proportion become hypermethylated during
development (reviewed in Bird 2002), and this correlates with
transcriptional silencing of the associated gene. In our study,
27 amplicons overlapped CpG islands, and 22 of these (i.e.,
80%) were hypomethylated in all tissues examined. Interest-
ingly, this proportion of hypomethylated CpG islands is
similar to that reported by Yamada et al. (2004), who analysed
the methylation status of CpG islands on human Chromo-
some 21q and found that 103 out of 149 CpG islands (i.e.,
70%) were hypomethylated.
In our study, CpG island amplicons situated in the
upstream ROIs were always hypomethylated, whereas hyper-
methylated CpG island amplicons were found only in the
intragenic regions. Among the intragenic CpG island
amplicons, those situated at the 59 end of the gene (i.e.,
overlapping exon 1, intron 1, or exon 2) were always
hypomethylated. A tissue-speciﬁc methylation proﬁle was
observed for the CpG island situated within exon 3 of the
tenascin-XB (TNXB) gene, which was hypomethylated in
muscle samples only. This hypomethylation correlates with
the temporally regulated and tissue-speciﬁc expression of
TNXB, which is abundantly expressed in connective tissues. It
has been suggested that TNXB has a role in limb, muscle, and
heart development (Burch et al. 1995), and, therefore,
epigenetic modiﬁcations at the TNXB CpG island may have
an important regulatory role (tissue speciﬁcity of methylation
proﬁles is discussed in more detail below). Interestingly, the
CpG island amplicon located within exon 3 of the HLA-G
gene spanned a methylation boundary, being hypomethylated
at the 59 end with a sharp transition to a hypermethylated
proﬁle at the 39 end. Overall, the results are consistent with
the prevailing model of CpG islands being regions of the
genome that are hypomethylated, especially when they occur
upstream or within the 59 end of the gene.
Tissue Specificity of the Methylation Profiles
DNA methylation proﬁles are complex and dynamic, and
can vary with developmental stage, tissue type, age, the alleles’
parent-of-origin, and also phenotype or disease state (re-
viewed in Bird 2002). In particular, the role of DNA
methylation in setting up and maintaining tissue-speciﬁc
expression patterns has received a lot of attention. However,
the extent of tissue speciﬁcity of DNA methylation proﬁles is
relatively unknown. The HEP pilot study involved the analysis
Figure 4. Bimodal Distribution of DNA
Methylation within the Human MHC
(A) Determined by direct sequencing/
ESME analysis (based on 86,374 single
CpGs in different tissue samples building
the median for measurement repeti-
tions).
(B) Determined by MALDI-MS (based on
1,019 MALDI measurements).
DOI: 10.1371/journal.pbio.0020405.g004
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Human Epigenome Projectof 32 samples (from different individuals) comprising seven
tissues: adipose, brain, breast, liver, lung, muscle, and prostate.
Upon comparison of the amplicon proﬁles, we found that
10% of all amplicons displayed differential methylation
between the tissue types (examples are shown in Figure 5).
Of these amplicons, 31% were located in the upstream
regions, a proportion that is in the same range as the total
number of upstream amplicons relative to intragenic
amplicons analysed in this study (see Table 1). We scanned
the literature and publicly available gene expression data-
bases to determine whether the cognate genes displayed
tissue-speciﬁc expression. An example is the complement
protein C2 mRNA, which normally has a long 59 upstream
region; in the liver, an additional transcript with a much
shorter 59 upstream region is expressed (Horiuchi et al. 1990).
In our study we found that a region that overlaps intron 2 and
exon 2 of the C2 gene was hypomethylated in liver samples
only (however, this region is downstream of the transcrip-
tional start sites of both forms of C2 mRNA). Another
example is DOM3Z, which is ubiquitously expressed but
occurs only at very low levels in the lung (Yang et al.1998), and
this correlates with a region overlapping exons 4 and 5 of
DOM3Z that is hypermethylated in lung (and brain) but
hypomethylated in the other tissues examined. It has also
been demonstrated that the murine complement factor B utilises
differential tissue-speciﬁc start sites (Garnier et al. 1995), and
in our analysis the human homologue is hypomethylated at a
region overlapping exons 3 and 4 only in liver. However, the
majority of the genes that were associated with tissue-speciﬁc
methylation proﬁles in our study did not show corresponding
tissue-speciﬁc expression proﬁles in a previously reported
whole human genome expression microarray analysis (Su et
al. 2002). Some of these genes are known to be associated with
various mRNA isoforms, but detection of such alternative
transcripts is quite difﬁcult with conventional microarray
analysis and usually requires more detailed analysis. It is also
possible that the tissue-speciﬁc methylation proﬁles we
observed in adult tissue may hint at tissue-speciﬁc expression
proﬁles that existed during early development, or they may
be associated with as yet unknown transcripts, e.g., non-
coding RNAs. Alternatively, there may be only a modest
proportion of genes in which tissue speciﬁcity of gene
expression is affected by methylation.
Inter-Individual Variation of Methylation Profiles
There is increasing evidence that an individual’s epigenetic
proﬁle can inﬂuence phenotype and susceptibility to various
diseases such as cancer, an example of such evidence being a
recent report linking the loss of imprinting at the IGF2 locus
with an increased risk of developing colorectal cancer (Cui et
al. 2003). In our study, nearly all loci displayed some degree of
heterogeneity, which probably has no bearing on the differ-
ences in genome function among individuals. However,
considerable differences in methylation proﬁles between
individual samples within a tissue were observed for a
number of amplicons. We calculated a median methylation
value for each individual sample and then compared these
values within each tissue type for each amplicon. A total of
118 amplicons displayed a difference of greater than 50%
between the lowest and highest median methylation values in
Figure 5. Example of METHANE Output
Showing Regions That Display Tissue-
Specific Methylation Profiles
The top colour-scale bar refers to the
degree of methylation (percent). The
bottom colour-scale bar refers to the
absolute difference in the methylation
level observed between tissues at a given
CpG site, and is therefore a measure of
the conﬁdence level for a CpG site to be
deﬁned as a MVP.
(A) The upper matrix represents an
amplicon that contains 18 CpG sites
within a 386-bp region overlapping exon
3, intron 3, and exon 4 of the complement
factor B gene. It is hypomethylated in
liver (median methylation is 17%) and
hypermethylated in all other tissues
examined (median methylation is
100%). The lower matrix shows pairwise
comparisons of the methylation values
for each CpG site between tissues.
(B) The upper matrix represents an
amplicon that contains 19 CpG sites
within a 550-bp region overlapping exon
3 and intron 3 of the DAXX gene. It is
relatively hypomethylated in breast (me-
dian methylation is 64%) compared with
the other tissues examined (median
methylation is 100%). The lower matrix
shows pairwise comparisons of the meth-
ylation values for each CpG site between
tissues.
DOI: 10.1371/journal.pbio.0020405.g005
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Human Epigenome Projectat least one tissue. Of these amplicons, 76% were intragenic,
which is a similar proportion to the overall number of
intragenic amplicons (71%; 181 out of 253 amplicons)
analysed in the study. This proportion is also similar to the
overall proportion of amplicons that showed tissue-speciﬁc
methylation proﬁles and were classiﬁed as intragenic (69%).
Although inter-individual variation for a given amplicon was
not observed in every tissue, there was no apparent tissue-
speciﬁc enrichment for inter-individual variability of meth-
ylation proﬁles.
Examples of amplicons that displayed signiﬁcant inter-
individual variation in methylation proﬁles include a region
overlapping the last exon in CYP21A2 that showed consid-
erable inter-individual variation in prostate (Figure 6A), and
a5 9 upstream region of tumour necrosis factor (LocusID 7124)
that varied signiﬁcantly between individuals in liver (Figure
6B). Although the differences could be attributable to the
technical variability inherent in our approach or the fact that
we did not control for age or sex of the tissue donors, it is also
possible that certain genotypes are associated with unique
epigenotypes. In a recent study, Van Laere et al. (2003)
mapped a porcine quantitative trait locus that affects muscle
growth, fat deposition, and heart size to an evolutionarily
conserved CpG island within the imprinted Igf2 gene. Pigs
inheriting the mutation from their sire had a 3-fold increase
in Igf2 expression in postnatal muscle (i.e., the quantitative
trait locus is paternally expressed). Furthermore, the muta-
tion abrogated in vitro interaction with a nuclear factor, and
this effect was phenocopied following in vitro DNA methyl-
ation of the region. Evidence for an interaction between
genotype and epigenotype at the IGF2 gene in humans has
also recently been reported (Murrell et al. 2004). Of the 3,273
unique CpG sites we analysed, 101 overlapped with known
SNPs (relatively evenly distributed over all amplicons), all
representing sites at which the CpG was lost (see Figure 1;
Table 1). The SNPs were extracted from dbSNP (http://
www.ncbi.nlm.nih.gov/SNP) and are annotated in the HEP
database. One could postulate that the gain or loss of one or
more critical CpG sites may affect the overall methylation
proﬁle of a locus and, consequently, promoter activity.
Alternatively, non-CpG SNPs located within an epigenetically
sensitive regulatory element could also inﬂuence the epige-
netic makeup of that region. Therefore, mutations in
regulatory sequences could inﬂuence epigenetic proﬁles,
resulting in altered phenotypes.
Analysis of Methylation Variable Positions by MALDI-MS
A major aim of the HEP is to identify genomic regions at
which DNA methylation proﬁles display statistically signiﬁ-
cant variation due to biological or environmental inﬂuences.
Therefore, based on the tissue-speciﬁc and inter-individual
variation in methylation proﬁles discussed above, we were
interested in establishing high-throughput assays for epige-
notyping. This involved the identiﬁcation (manually or using
the METHylation ANalysis Engine [METHANE]) of methyl-
ation variable positions (MVPs), which we deﬁne as CpG sites
that have statistical power to discriminate between different
biological samples or states. In other words, by assaying the
methylation state of just a few select CpG sites within a given
region, information can be inferred about the tissue source
or disease state. Such a high-throughout MVP epigenotyping
method was recently developed based on the GOOD assay
(Tost et al. 2003). This recently developed epigenotyping
assay allows for accurate discrimination of methylation levels
that differ by 5% or more. Furthermore, MALDI-MS is a
relatively inexpensive method that offers a high degree of
automation and integration and that has no requirement for
sample puriﬁcation. Assays for 231 MVPs in 77 amplicons,
including all those that displayed differential methylation
proﬁles between different tissue types or inter-individual
variability, were designed and analysed in a triplex format
(i.e., methylation levels at three independent CpG sites are
analysed in one assay). A subset of 11 MALDI-MS assays is
shown in Figure 7.
Comparison of Methylation Profiles with Independent
Gene Expression Data
The primary function of epigenetic modiﬁcations is to
modulate gene expression: a speciﬁc combination of epige-
netic modiﬁcations at regulatory elements, notably pro-
moters and enhancers, inﬂuences the transcriptional state
of a gene (reviewed in Bird 2002). In many cancers, aberrant
epigenetic modiﬁcations occur within CpG islands that
overlap promoters (some of which are candidate tumour
suppressors), which is thought to result in aberrant tran-
scription of the cognate gene, thus contributing to tumour
progression.
We compared the amplicon methylation proﬁles with the
human genome expression patterns available from the
Genomics Institute of the Novartis Research Foundation
Gene Expression Atlas database (http://expression.gnf.org).
Figure 6. Example of METHANE Output
Showing Regions That Display Inter-Indi-
vidual Variation of Methylation Profiles
(A) Example of a region that displays
signiﬁcant inter-individual variation, es-
pecially in prostate. The matrix repre-
sents an amplicon that contains 27 CpG
sites within a 527-bp region overlapping
the last exon of the CYP21A2 gene.
(B) Another example of a region that
displays signiﬁcant inter-individual var-
iation. The matrix represents an ampli-
con that contains 13 CpG sites within a
453-bp region overlapping the 59 UTR
and exon 1 of the tumour necrosis factor
gene.
DOI: 10.1371/journal.pbio.0020405.g006
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mRNA expression data obtained by Su et al. (2002) using
human U95A Affymetrix microarray chips. We calculated a
median methylation value for each amplicon (see Materials
and Methods). As mentioned above, the methylation proﬁles
displayed a bimodal distribution, with more than 90% of the
amplicons being either hypomethylated (median methylation
of 30% or less) or hypermethylated (median methylation of
70% or greater). Therefore, to perform the analyses we
divided the amplicons into two categories: hypomethylated
(methylation less than 50%) and hypermethylated (methyl-
ation greater than 50%) (see Materials and Methods). We then
compared the range of expression values associated with
hypomethylated amplicons with those of hypermethylated
amplicons. Most genes on the U95 microarray are repre-
sented by multiple probes, and, in a few cases, contradictory
expression values were obtained for the same gene, in which
case the gene was excluded from our analyses. Analyses were
performed for liver, lung, and prostate samples only (Figure
8), since appropriate Gene Expression Atlas data were
unavailable for the other tissues. For prostate and liver, a
signiﬁcant difference was found between expression levels
associated with hypomethylated versus hypermethylated up-
stream amplicons: hypomethylated upstream amplicons
correlated with a wide range of expression levels whereas
hypermethylated upstream amplicons correlated with a lack
of expression (p , 0.0001 for prostate and p , 0.01 for liver).
The intragenic amplicons did not show any correlation
between methylation and expression levels (p . 0.3 for both
prostate and liver). A list of all upstream amplicons included
in the analysis is given in Table S2.
For the lung samples there was no signiﬁcant correlation
between expression and methylation state for amplicons
within the upstream or intragenic categories (p . 0.3 for both
categories). Although the lung data show the same trend as
the prostate and liver data, the lung hypomethylated data
contained a number of outlier data points representing very
high expression values (as shown in Figure 8 by the unﬁlled
circles). The overall trend of the data suggests that these data
may be artefactual, but there is nothing that indicates these
data points are not real. These data points were enough to
inﬂuence the analysis such that we could not ﬁnd a signiﬁcant
difference in the expression of between hypo- and hyper-
methylated lung genes. If the data points are real, the lack of
correlation for the lung samples may be due to inconsisten-
cies within the expression or methylation datasets for lung.
Alternatively, there may be additional regulatory elements
that inﬂuence the expression state of the analysed genes in
the lung.
Overall, the ﬁndings are consistent with a model in which
the DNA methylation proﬁle of the upstream region of the
gene is an informative indicator of the expression of the
cognate gene, speciﬁcally, in which hypermethylation within
the upstream region is associated with transcriptional
silencing. Furthermore, the data also suggest that epigenetic
modiﬁcations within the upstream regions inﬂuence the
transcriptional state of a signiﬁcant number of the genes
within the MHC. This is supported by the study of Jackson-
Grusby et al. (2001) in which they employed homogeneous
cultures of primary mouse embryonic ﬁbroblasts and used
the Cre-loxP system to conditionally inactivate Dnmt1, an
enzyme that methylates DNA. They found that in the absence
of Dnmt1, several mouse MHC class I genes showed altered
expression proﬁles.
Concluding Remarks
One of the principal challenges in the post-genomic era is
to provide a holistic view of genome function, a challenge
which is currently being addressed by several large-scale
studies of the transcriptome, proteome, metabolic networks,
and haplotype maps. The HEP is therefore timely, since DNA
methylation is an indispensable part of the genome’s
regulatory mechanisms. Here we have described the pilot
study for the HEP—DNA methylation proﬁling of the MHC
region—which is the ﬁrst systematic large-scale study of
methylation proﬁles at the sequence level within a multi-
Figure 7. Comparison of Methylation
Values Measured in Five Tissues and Eleven
Amplicons Using MALDI-MS and ESME
Analysis of Directly Sequenced PCR Prod-
ucts
Each column is a tissue sample, each row
a CpG site. Data are ordered in blocks by
tissue type and amplicons. Positions of
measurements for MALDI-MS (A) corre-
spond to those for ESME analysis (B).
The methylation values are colour coded
from 0% methylation (yellow) to 100%
methylation (blue), with intermediate
methylation levels represented by shades
of green. White indicates missing meas-
urement values.
DOI: 10.1371/journal.pbio.0020405.g007
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Human Epigenome Projectmegabase region of the human genome. For this project, we
developed an integrated pipeline for high-throughput meth-
ylation analysis using bisulphite DNA sequencing, MVP
discovery, and epigenotyping by MALDI-MS, and created an
integrated database (http://www.epigenome.org) for public
access to the data generated by the study. The results from
the pilot study demonstrate that a signiﬁcant proportion of
the analysed loci within the MHC show tissue-speciﬁc
methylation proﬁles, and inter-individual methylation differ-
ences are common. Furthermore, the tissue-speciﬁc differ-
ences in DNA methylation suggest that epigenetic
mechanisms are involved in the use of alternative transcrip-
tional start sites. We have also shown that the generated
methylation data allow the identiﬁcation of MVPs that can be
typed with high quantitative resolution and sensitivity using
MALDI-MS, providing a tool for large population-based
studies and for diagnosing diseases in the future.
The study reported here lays the foundation for the HEP,
which aims to analyse the methylation state of the regulatory
regions of all annotated genes in most major cell types and
their diseased variants. In the ﬁrst phase, which is well
underway, we are analysing the DNA methylation proﬁles of
over 5,000 amplicons (representing a 20-fold scale-up relative
to the pilot HEP study reported here) associated with nearly
all the annotated genes (approximately 3,000) on human
Chromosomes 6, 13, 20, and 22. The excellent genomic
annotation available for these four chromosomes, e.g., high-
quality transcript information and location of SNPs, will
enable us to perform comprehensive analyses linking the
epigenetic information gained from the HEP with the
underlying genetic information. Samples from over 40
different individuals representing 20 tissues will be used in
the study.
The resulting data will generate a map that complements
other large-scale efforts that are linking our knowledge of
gene sequence and cellular phenotypes: studies involving
DNA sequencing, SNPs, histone modiﬁcations, and tran-
scriptome and proteomic analyses. The epigenome map will
be invaluable for understanding gene regulation and the
interactions between genes in normal and disease states. It
will offer new explanations in well-studied areas such as
cancer research, and will also provide a basis for novel
approaches to research on environmental effects, nutrition,
and ageing (Eckhardt et al. 2004). The HEP also promises to
provide DNA methylation markers for disease states, and new
targets for drug development and diagnostic applications
based on DNA methylation research are already emerging
(Cairns et al. 2001). Current efforts to target the epigenomic
machinery of cells with drugs have global effects (Besterman
and McLeod 2000; Lubbert 2000; Munster et al. 2001), and
Figure 8. Comparison of DNA Methylation
with Gene Expression
Amplicons generated from prostate (yel-
low), lung (blue), and liver (green) sam-
ples were divided into two categories:
‘‘upstream’’ and ‘‘intragenic’’. The me-
dian methylation values for the ampli-
cons were calculated as described in the
text, and these were then classiﬁed as
hypomethylated (median methylation
less than 50%) or hypermethylated (me-
dian methylation greater than 50%), and
plotted against the cDNA microarray
expression data available at http://ex-
pression.gnf.org (Su et al. 2002). The
expression values are expressed as aver-
age difference values (ADVs) for each
gene. The average difference value is
computed using Affymetrix software and
is proportional to mRNA content in the
sample, with a value of 200 being a
conservative cut-off below which a gene
can be classiﬁed as being not expressed.
The average difference values are the
mean of 2 or 3 independent experi-
ments. For prostate and liver, the ex-
pression levels associated with the
hypermethylated upstream amplicons
were signiﬁcantly lower than the expres-
sion levels associated with the hypome-
thylated upstream amplicons (p , 0.0001
for prostate and p , 0.01 for liver). For
lung, there was no signiﬁcant difference
between the expression levels associated
with the hypermethylated upstream am-
plicons and those of the hypomethylated
upstream amplicons (p . 0.3). There was
no correlation between expression and
methylation for the intragenic amplicons
for any of the three tissues (p . 0.3). The width of the bars is indicative of the number of amplicons in each category: prostate upstream,
hypermethylated (n = 9); prostate upstream, hypomethylated (n = 15); prostate intragenic, hypermethylated (n = 109); prostate intragenic,
hypomethylated (n = 53); liver upstream, hypermethylated (n = 9); liver upstream, hypomethylated (n = 14); liver intragenic, hypermethylated
(n = 115); liver intragenic, hypomethylated (n = 45); lung upstream, hypermethylated (n = 9); lung upstream, hypomethylated (n = 13); lung
intragenic, hypermethylated (n = 112); and lung intragenic, hypomethylated (n = 57).
DOI: 10.1371/journal.pbio.0020405.g008
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lating knowledge in the new ﬁeld of epigenomics.
Materials and Methods
Tissue samples. Human tissue samples were obtained from the
National Disease Research Interchange (Philadelphia, Pennsylvania,
United States) and consisted of tissue material from healthy
individuals. Tissue samples included seven different tissue types
(adipose, brain, breast, lung, liver, prostate, and muscle) from 32
different individuals (Table S1). DNA was extracted using standard
protocols (Sambrook et al. 1989).
Bisulphite conversion. Bisulphite treatment of genomic DNA was
p e r f o r m e dw i t hm i n o rm o d i ﬁ c ations to a method described
previously (Olek et al. 1996).
Amplicon design and PCR. Primers were designed to be at least 21
bases (GþC   30%) and to contain at least two bases complementary
to bisulphite-converted sequence to increase the speciﬁcity. To
ensure that the primers were not biased for either hypomethylated or
hypermethylated sequences, controls were performed using bisul-
phite-converted unmethylated or in vitro methylated target sequen-
ces. PCRs were performed in 96-well plates on MJ Research (Waltham,
Massachusetts, United States) thermocyclers in a ﬁnal volume of 25 ll
containing 250 lM dNTPs, 1X PCR Buffer (Qiagen, Valencia,
California, United States), 10 pmol each of forward and reverse
primer, 1 U Taq polymerase (Qiagen), and 8 ng of bisulphite-treated
genomic DNA. Water-only controls were also included in each 96-
well PCR plate. The cycling conditions were 95 8C for 15 min followed
by 40 cycles of 95 8C for 60 s, 55 8C for 45 s, and 72 8C for 90 s, and a
ﬁnal extension step of 10 min at 72 8C. The PCR amplicons for some
of the genomic regions that displayed heterogeneous levels of CpG
methylation were sub-cloned using the pGEM-T Easy Vector System
according to the manufacturer’s instructions (Promega, Madison,
Wisconsin, United States). The clones were sequenced on ABI 3700
capillary sequencers (Applied Biosystems, Foster City, California,
United States) using ABI Prism Big Dye terminator V 3.1 sequencing
chemistry.
Sequencing. PCR amplicons were puriﬁed using MultiScreen PCR
plates (Millipore, Billerica, Massachusetts, United States) and
sequenced directly in forward and reverse directions with the same
primers used in the PCR. Sequencing was performed on ABI 3700
capillary sequencers using ABI Prism Big Dye terminator V 3.1
sequencing chemistry.
Analysis and database generation. Quantitative methylation rates
were estimated from sequence traces using the ESME software (Lewin
et al. 2004). This involved appropriate quality control, normalisation
of signals, correction for incomplete bisulphite conversion, and
mapping of positions in the trace ﬁle to CpGs in reference sequences
as described in Lewin et al. (2004). Amplicons were mapped to the
human genome assembly (NCBI34) using BLAST (Altschul et al. 1990)
and CrossMatch (http://www.genome.washington.edu/UWGC/analysi-
stools/Swat.cfm). Using these offsets the positions of CpG dinucleo-
tides were determined in genomic coordinates. Positional data were
then loaded into an LDAS database (http://www.biodas.org) suitable
for serving to applications using the distributed annotation system
(DAS) XML format (Dowell et al. 2001). HEP methylation data
converted to DAS format could then be incorporated dynamically
into any third-party applications (such as ENSEMBL) capable of
understanding DAS. A Web-based, ENSEMBL-like genome browser,
driven entirely from DAS data, was created for displaying HEP data
and is publicly available at http://www.epigenome.org. The data
reported in the pilot HEP study are subject to the HEP’s data release
policy (http://www.sanger.ac.uk/PostGenomics/epigenome/drp.shtml).
Kolmogorov-Smirnov tests conﬁrmed that the methylation data
did not follow Gaussian distribution (p ,0.0001 in all cases). We
therefore used the Mann-Whitney U test (a non-parametric test that
compares the medians of two unpaired groups of samples that do not
follow a Gaussian distribution) to perform three different compara-
tive analyses for methylation proﬁles: (i) upstream versus intragenic
amplicons, (ii) within the upstream amplicon category, CpG sites
located within the 59 UTR versus CpG sites not located within the 59
UTR but still within 2 kb of the ﬁrst start codon, and (iii) within the
intragenic amplicon category, intronic versus exonic CpG sites.
We designed a software package, METHANE, to identify and
generate graphical views of MVPs (see Figures 5 and 6). This tool uses
the same DAS data source as the Web browser to generate graphical
views but adds additional analysis facilities to compare and display
relative methylation level differences in pairwise comparisons.
METHANE provides options to compare CpG methylation level
differences calculated from either simple averages or medians per
tissue or per site. METHANE can export data as tabular text output
or as images in SVG, PDF, or postscript formats and is available on
request from the authors.
Epigenotyping by mass spectrometry. Assays, based on the GOOD
assay for DNA methylation analysis (Tost et al. 2003), were established
for amplicons displaying differential methylation between tissue
types or inter-individual variability in the sequencing effort. In most
cases, three MVPs within an amplicon were simultaneously queried
and analysed. Assay volumes started at 3 ll for PCR, with 2-ll
additions for shrimp alkaline phosphatase treatment, primer exten-
sion, and 59-phosphodiesterase digest, and the addition of 10 llo f
alkylation mix in the respective reaction steps. After dilution with
acetonitrile, 0.5-ll samples were transferred to a matrix coated
MALDI target plate. All liquid handling was carried out with
automated liquid-handling robotics (BasePlate, The Automation
Partnership, Royston, United Kingdom). All MALDI-MS analyses
were performed with positive ion mode detection on Bruker Autoﬂex
MALDI mass spectrometers (Bruker Daltonics, Billerica, California,
United States), equipped with target-plate-changing robots.
To ensure accurate quantiﬁcation and to compensate for the
c o m m o np r e f e r e n t i a la m p l i ﬁ c a t i o ni nb i s u l p h i t e - t r e a t e dD N A ,
triplicate calibration standards from 0% to 100% methylation in
25% increments were included into the analysis. Statistical param-
eters were deﬁned to compensate for factors complicating quantiﬁ-
cation by MALDI-MS, such as bad reproducibility of the
crystallisation, different rates of ionisation of analytes, and signal-
to-signal interactions. Quantitative results were obtained with high
accuracy when 200 laser shots were accumulated on a sample spot,
and eight preparations accounted for differences in the sample
preparations. Thus, in total, a quantitative data point is obtained
from the average of 1,600 individual spectra and calibrated with the
help of mixtures with a known degree of methylation. Success rates
are above 97%, and standard deviation for data points is less than
2%.
Comparison of DNA methylation with mRNA expression levels.
The methylation data were compared with data in the Gene
Expression Atlas database (Su et al. 2002) that contains human
transcript data based on the U95 build of Unigene, Affymetrix U95A
chip. We calculated methylation values for each amplicon using the
median of the methylation values for each CpG site within that
amplicon. A quantile plot indicated a strongly non-normal distribu-
tion of the data, speciﬁcally, platykurtosis (one of two different kinds
of kurtosis) demonstrating a bimodal distribution. Therefore, for the
purposes of simpliﬁed statistical analysis, amplicons were classiﬁed as
either hypermethylated or hypomethylated dependent on whether
their median methylation value was either greater than or less than
50%, respectively. We performed methylation versus expression
comparisons after removing the data that corresponded to multiple
probes that gave contradictory expression patterns for the same gene
on the U95 microarray. Equality of mean expression levels between
hypermethylated and hypomethylated datasets was tested using a
Welch two-sample (unpaired) t-test.
Supporting Information
Table S1. Tissues Used in the HEP Pilot Study
Found at DOI: 10.1371/journal.pbio.0020405.st001 (63 KB DOC).
Table S2. Upstream Amplicons Included in the Comparative Analysis
of DNA Methylation with mRNA Expression
Found at DOI: 10.1371/journal.pbio.0020405.st002 (32 KB DOC).
Accession Numbers
The LocusLink (http://www.ncbi.nlm.nih.gov/projects/LocusLink/) ac-
cession numbers for the genes and gene products discussed in this
paper are C2 (LocusID 717), CYP21A2 (LocusID 1589), DOM3Z
(LocusID 1797), HLA-G (LocusID 3135), IGF2 (LocusID 3481), TNXB
(LocusID 7148), and tumour necrosis factor (LocusID 7124).
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